Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Scientists from Tibotec Pharmaceuticals Ltd. presented data on several new compounds for the treatment of HIV/AIDS at the 12th Conference on Retroviruses and Opportunistic Infections (CROI), held February 22-25 in Boston, MA, USA.
Scientists from The Queensland Institute of Medical Research (QIMR) have found that a group of HIV drugs known as protease inhibitors may also be effective for treating or preventing malaria.
The study found protease inhibitors inhibited the growth of P. falciparum, the malaria parasite that causes most disease. These findings may also expose a previously unexplored vulnerability in the parasite that could lead to a new class of anti-malarial drug.
The Company is seeking accelerated approval of tipranavir and has requested a priority, six-month review of the NDA. Priority review designation is based upon whether a drug provides a significant improvement in the treatment of a serious or life-threatening disease.
Virologists from the Katholieke Universiteit Leuven in Belgium report that chloroquine, a widely used antimalarial drug, exhibits antiviral activity against the SARS coronavirus. Chloroquine is an inexpensive and safe drug available worldwide.
Bristol-Myers Squibb has announced that Sustiva® (efavirenz) has received approval from the U.S. Food and Drug Administration to include new long-term virologic and clinical data from BMS Study 006 in its prescribing information.
The agreement resolves the two lawsuits brought by AHF against Abbott over the company's price increase for its HIV/AIDS drug, Norvir® (ritonavir).
HIV treatment regimens containing the protease inhibitor (PI) LEXIVA® (fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) or lopinavir (LPV) and ritonavir (LPV/r) were effective in suppressing HIV in patients who had failed prior PI-containing regimens, according to information presented at the International AIDS Conference (IAC).
Health Canada, in association with Bristol-Myers Squibb Canada, is advising Canadians to consult with their health care professionals if they are currently being treated with the antidepressant trazodone in combination with any of the following medications: ketoconazole (an antifungal agent), ritonavir and indinavir (protease inhibitors used in the treatment of HIV), or carbamazepine (an anti-epileptic therapy).
An Italian study has provided evidence that HIV drugs called protease inhibitors may increase the risk of artery "plaques."
A broad coalition of AIDS advocates and patients will come together in protest over Abbott Laboratories' recent unprecedented 400% price hike on Norvir (ritonavir), their key AIDS drug.
Roche has announced results from a study demonstrating that the new boosted dosing regimen for its protease inhibitor Invirase(R) (saquinavir 1000 mg with ritonavir 100 mg twice-daily) has no significant interactions when it is co-administered with tenofovir disoproxil fumarate (300 mg once-daily).